血脂康对不稳定型心绞痛患者血脂、血清氧化修饰低密度脂蛋白、C反应蛋白和纤维蛋白原含量的影响

Effect of Xuezhikang on Blood Lipids, Serum Oxidized Low Density Lipoprotein, C-reactive Protein and Fibrinogen in Patients with Unstable Angina Pectoris

目的 :探讨血脂康的调脂作用及其对不稳定型心绞痛患者血清氧化修饰低密度脂蛋白、C反应蛋白、纤维蛋白原水平及预后的影响。方法 :分别给予患高脂血症的不稳定型心绞痛患者血脂康 (0 6 g/次 ,每天 2次 )口服连续 2个月、再半量服用 2个月 ;血脂正常的不稳定型心绞痛患者连续口服维生素E 4个月。比较入选时、治疗 1个月末、2个月末两组患者上述 3项指标的血清值及血脂水平 ;对比两组患者 4个月内终点事件发生率。结果 :血脂康应用 1个月后即可有效降低TC、LDL C水平 ,2个月后疗效进一步提高 ,其降低TG、升高HDL C在 2个月后起效 ;与维生素E相比 ,血脂康应用 2个月后能显著降低患者血清氧化修饰低密度脂蛋白、C反应蛋白、纤维蛋白原水平 ;降低 4个月内患者终点事件发生率。结论 :血脂康具有良好调脂效果 ,且能抑制斑块内炎症的发展 ,有利于不稳定型心绞痛患者预后的改善。

Objective: To study the lipid regulatory effect of Xuezhikang (XZK) and its effects on serum oxidized low density lipoprotein (OX-LDL), C-reactive protein (CRP) and fibrinogen (FIB) in patients with unstable angina pectoris (UAP). Methods: UAP patients with hyperlipidemia were treated with XZK 0.6 g, orally taken, twice a day for 2 successive months followed by half dosage for 2 months. To UAP patients with normal blood lipids, Vit E was given orally for 4 months. Levels of blood lipids, OX-LDL, CRP, FIB at the time of entry, 1st and 2nd month of the therapeutic course were observed and end-point events in the two groups was compared. Results: XZK can reduce the serum level of total cholesterol, low density lipoprotein after being administered for 1 month, and the effect further elevated after 2 months. Its effect in lowering triglycerides and increasing high density lipoprotein initiated after 2 months administration. Compared with effect of Vit E, XZK can significantly lower the serum OX-LDL, CRP and FIB after 2 months administration, and reduce the end-point events in 4 months. Conclusion: XZK has good regulatory effect on blood lipids, it also can inhibit the development of inflammation in coronary plaque, therefore, is beneficial to the prognosis of UAP patients.